Spire Wealth Management’s Maravai LifeSciences MRVI Stock Holding History

Spire Wealth Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,700	Closed	-$71K	–	2740
2021 Q4	$71K	Buy	+1,700	New	+$68.9K	﹤0.01%	1555
2021 Q2	–	Sell	-1,200	Closed	-$40K	–	2822
2021 Q1	$40K	Buy	+1,200	New	+$39.8K	﹤0.01%	1843

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Spire Wealth Management's MRVI Position: Q1 2022 in Review

Spire Wealth Management sold out of Maravai LifeSciences (MRVI) in Q1 2022, closing a stake of 1,700 shares — an estimated $71K sold.

Spire Wealth Management first reported a position in MRVI in Q1 2021 and held it in 2 quarters. The position peaked at $71K in Q4 2021. 235 funds tracked by Wall St. Rank hold MRVI as of Q1 2022.

Spire Wealth Management reported no remaining Maravai LifeSciences position as of Q1 2022 after selling out during the quarter.
Spire Wealth Management sold 1,700 Maravai LifeSciences shares in Q1 2022, an estimated $71K.
Spire Wealth Management first reported a position in Maravai LifeSciences in Q1 2021 and held it in 2 quarters.
Spire Wealth Management's Maravai LifeSciences position peaked at $71K in Q4 2021.
235 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.